Loading viewer...
investor_presentation
Format: PDF investor_presentation
Protagonist Therapeutics presents its core competencies in peptide-based medicine development, featuring lead programs including JNJ-2113 for psoriasis in Phase 3 trials and rusfertide for polycythemia vera. The presentation outlines the company's expertise in peptide chemistry, oral stability, and GI-restricted targeted delivery, supported by a collaboration with Janssen Biotech.
investor_presentation
59 Pages
adidas
Everest Kanto Cylinder Q1 FY23 Investor Presentation 2022
investor_presentationinvestor_presentation
34 Pages
Everest Kanto Cylinder Limited